Glaucoma-Protective Human Single-Nucleotide Polymorphism in the Angpt2 Locus Increased ANGPT2 Expression and Schlemm Canal Area in Mice - Brief Report

Naoki Kiyota, Tuncer Onay, Phoebe Leeaw, Pan Liu, Dilip K. Deb, Benjamin R. Thomson, Ayellet V. Segrè, Janey L. Wiggs, Susan E. Quaggin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: The ANGPT (angiopoietin)-TEK (tyrosine kinase, endothelial) vascular signaling pathway plays a key role in the formation of Schlemm canal, and loss-of-function mutations in the TEK or ANGPT1 gene are associated with primary congenital glaucoma in children. In genome-wide association studies, an association was identified between protection from primary open-angle glaucoma and the single-nucleotide polymorphism rs76020419 (G>T), located within a predicted miR-145-binding site in the 3′ untranslated region of ANGPT2. To date, the functional impact of this variant in the anterior chamber of the eye remains largely unexplored. METHODS: MT (mutant) mice harboring an orthologous rs76020419 minor allele (T) were generated using CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat-associated 9). Plasma and tissue samples, including eyes, were collected, and ANGPT2 expression was quantified using ELISA. Anterior segments from eyes were collected from WT (wild-type) and MT mice, and Schlemm canal area was quantified. RESULTS: In the MT group, higher ANGPT2 concentrations were observed in the plasma, lungs, kidneys, and eyes (P=0.0212, P<0.001, P=0.0815, and P=0.0215, respectively). Additionally, the Schlemm canal was larger in MT mice compared with WT mice (P=0.0430). CONCLUSIONS: The rs76020419 minor allele (T) is associated with increased levels of ANGPT2 and a larger Schlemm canal in mice. These findings suggest a potential protective mechanism in glaucoma.

Original languageEnglish (US)
Pages (from-to)2207-2212
Number of pages6
JournalArteriosclerosis, thrombosis, and vascular biology
Volume44
Issue number10
DOIs
StatePublished - Oct 1 2024

Funding

This work was supported by the National Institutes of Health (NIH) R01EY025799-05 and NIH P30DK114857 to S.E. Quaggin, NIH R01 EY032609, a Bright Focus Foundation New Investigator fellowship, the Northwestern University Transgenic and Targeted Mutagenesis Laboratory, the Center for Advanced Microscopy of the Feinberg School of Medicine , and a Cancer Center Support Grant (NCI CCSGP30 CA060553). S.E. Quaggin is listed as an inventor in patents related to the therapeutic targeting of the ANGPT (angiopoietin)-TEK (tyrosine kinase, endothelial) pathway in ocular hypertension and glaucoma and is a founder and owns stock in Mannin Research. Additionally, S.E. Quaggin receives consulting fees from AstraZeneca and Roche/Genentech and is a member of the board of directors of AbbVie. B.R. Thomson has applied for a patent related to the therapeutic targeting of the ANGPT-TEK pathway. Unrelated to this research, B.R. Thomson has received research funding from Bayer. The other authors report no conflicts.

Keywords

  • angiopoietins
  • glaucoma
  • kidney
  • microRNAs
  • Schlemm canal

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Glaucoma-Protective Human Single-Nucleotide Polymorphism in the Angpt2 Locus Increased ANGPT2 Expression and Schlemm Canal Area in Mice - Brief Report'. Together they form a unique fingerprint.

Cite this